Clarity Pharmaceuticals has completed final follow-up assessments for every participant in its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. Topline results from AMPLIFY and the related CLARIFY trial are expected in the first half of 2027, with the data intended to support US FDA applications.
- Final follow-up assessments completed for all AMPLIFY participants
- Phase III trial targets recurrent prostate cancer after initial treatment
- Coprimary endpoints cover correct detection rate and positive predictive value
- Topline AMPLIFY and CLARIFY data expected in the first half of 2027
- Clarity plans rolling US FDA NDA submissions under Breakthrough Therapy designation
AMPLIFY Moves Into Final Data Analysis
Clarity Pharmaceuticals (ASX:CU6) has cleared a significant execution milestone in its prostate cancer imaging program, completing final follow-up assessments for all participants in the registrational Phase III AMPLIFY trial. The study is now moving through final data entry and analysis, with topline results expected in the first half of calendar 2027.
AMPLIFY is testing 64Cu-SAR-bisPSMA PET/CT in men whose prostate-specific antigen levels are rising or detectable after initial definitive treatment. The non-randomised, single-arm, open-label trial is designed to assess whether the imaging agent can detect biochemical recurrence at PSA levels above 0.2 ng/mL across clinical sites in the United States and Australia.
Coprimary Endpoints Target Recurrence Detection
The study’s coprimary endpoints are participant-level correct detection rate and region-level positive predictive value. Both are being assessed independently for same-day imaging, conducted one to four hours after administration, and next-day imaging at roughly 24 hours. Exploratory analyses will also compare 64Cu-SAR-bisPSMA with standard-of-care PSMA PET agents.
AMPLIFY began in May 2025 and reached its target enrolment of approximately 220 participants in March 2026. The final follow-up milestone comes after the company’s AMPLIFY recruitment milestone, which earlier coverage reported had reached 232 participants. No efficacy or safety results have been disclosed in the latest announcement.
FDA Pathway Gains Breakthrough Designation
The regulatory backdrop is favourable but not conclusive. The US Food and Drug Administration recently granted Breakthrough Therapy designation to 64Cu-SAR-bisPSMA for biochemical recurrence, supported by earlier COBRA and Co-PSMA studies alongside real-world evidence. Clarity says it intends to begin rolling submissions of modules for a New Drug Application under that designation once the pivotal data are available.
That designation may help streamline development and review, but it does not establish that the product is safe, effective or approvable. 64Cu-SAR-bisPSMA remains unregistered, and the company has stated that commercial availability is not guaranteed.
CLARIFY Creates a Second 2027 Catalyst
The AMPLIFY readout is expected alongside data from CLARIFY, Clarity’s other registrational Phase III trial of 64Cu-SAR-bisPSMA. CLARIFY is evaluating diagnostic performance in prostate cancer patients scheduled for radical prostatectomy and pelvic lymph-node dissection, with final participant assessments expected during 2026. The study had already entered its patient follow-up phase after recruitment was completed, as reported in the completed CLARIFY recruitment update.
Together, the two trials are intended to support separate US FDA applications: AMPLIFY in biochemical recurrence and CLARIFY in patients undergoing definitive treatment. The next hard evidence for that regulatory ambition will not arrive with this milestone, however. It will come when the company releases the underlying diagnostic results in the first half of 2027.
Bottom Line?
The operational risk has shifted from recruitment to data quality, endpoint performance and whether the two Phase III readouts can support the rolling FDA submission strategy.
Questions in the middle?
- Will AMPLIFY meet its correct detection rate and positive predictive value endpoints across both imaging windows?
- How will 64Cu-SAR-bisPSMA compare with standard-of-care PSMA PET agents in the planned analyses?
- Will the AMPLIFY and CLARIFY data be sufficient for Clarity to begin rolling NDA submissions in 2027?